Latest News Feed
Proof-of-concept SHEPHERD study will assess SUL-238's effects on mitochondrial function in patients with Parkinson's disease.
GEN announces approval in the Netherlands to initiate patient enrollment in April 2026 for the Phase II Proof of Concept trial of its novel drug candidate SUL-238, Targeting Mitochondrial Dysfunction in Patients with Parkinson's Disease.
Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly volunteers, supporting its advancement into further clinical development for Alzheimer's and other neurodegenerative diseases.
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable pharmacokinetic profile and high brain penetration. These findings support the advancement of SUL-238 into further clinical development for Alzheimer's and other neurodegenerative diseases.
